Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QL0911 in Chemotherapy-Induced Thrombocytopenia
NCT05851027Phase 3Completed
- Sponsor
- Qilu Pharmaceutical
- Start
- Jan 2021
- Primary completion
- Sep 2021
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 3 trial of QL0911 in chemotherapy-induced thrombocytopenia (CIT), sponsored by Qilu Pharmaceutical. Started Jan 2021; status: completed.
02
Drugs
QL0911
03
Conditions
chemotherapy-induced thrombocytopenia (CIT)
Beyond the preview
Go deeper on NCT05851027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05851027.